# Signadori Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/signadori-bio

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.signadoribio.com
- Latest round: Seed (May 5, 2026)
- Investors on record: 3

## About

Based in France, Signadori Bio SAS specializes in next-generation in vivo monocyte immunotherapy, focusing on enhancing the body’s immune response against solid tumors through advanced therapeutic technologies.Signadori Bio SAS was founded in 2025 in Paris, France, and specializes in developing innovative monocyte immunotherapies for cancer treatment. The company was co-founded by Jean-Luc Perfettini (CSO) and Nathalie Chaput. The current CEO of company is Selwyn Ho as of June 2026. In May 2026, Signadori Bio raised seed funding co-led by Taiho Ventures, Sofinnova Partners, and Invivo Partners. Signadori Bio specializes in next-generation in vivo monocyte immunotherapy, primarily targeting solid tumors. The company’s core offerings revolve around its proprietary p21-engineered monocytes, designed to enhance the natural tumor-killing abilities of monocytes in the bloodstream. Once administered, these engineered monocytes differentiate into two key immune cell types: macrophages and dendritic cells. Macrophages exhibit heightened phagocytic activity to effectively eliminate tumor cells, while dendritic cells present tumor-associated antigens to activate the adaptive immune response. The technologies underpinning these therapies stem from pioneering research at Institut Gustave Roussy, with exclusive licenses for p21 technology globally. Signadori Bio aims to deliver these therapies to oncology centers and hospitals across Europe and North America, addressing the medical need for effective treatments for solid tumors.Signadori Bio generates revenue through partnerships, R&D collaborations, and clinical trials as it advances its monocyte therapies toward market readiness. The company engages with healthcare providers and research institutions to facilitate therapy development, incorporating both direct-to-consumer and B2B transactions. Revenue can arise from licensing agreements for its proprietary p21 technologies, clinical trial collaborations, and subscription models for ongoing R&D support. The company will use the May 2026 funding to support its product development and expansion plans initiatives.

## Funding rounds

- Seed, May 5, 2026 — Sofinnova Partners, Taiho Ventures, Invivo Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Seed
- Invivo Partners (https://capitalatlas.ai/funds/invivo-partners) — Seed